Status:
RECRUITING
BENLYSTA® Special Drug Use Investigation
Lead Sponsor:
GlaxoSmithKline
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
Brief Summary
The objective of this study is to collect and assess the information about long-term safety and effectiveness of Benlysta for intravenous injection and Benlysta for subcutaneous injection (hereinafter...
Eligibility Criteria
Inclusion
- The study will include all subjects to whom Benlysta is administered. In addition, among subjects who start administration after launch, those to whom Benlysta has already administered before the conclusion of the contract and those who has already started administration at diagnosis, because of hospital transfer, etc. will be included as well.
Exclusion
- N/A
Key Trial Info
Start Date :
January 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 26 2025
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03370263
Start Date
January 15 2018
End Date
June 26 2025
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Hiroshima, Japan, 730-0001